title: Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
abstract: Golimumab is a fully human antitumor necrosis factor alpha (TNF-alpha) monoclonal antibody that is being developed for intravenous and subcutaneous administration. To assess the pharmacokinetics and safety of the intravenous formulation of golimumab, 36 adult subjects with rheumatoid arthritis were randomly assigned to receive a single infusion of placebo or golimumab (0.1, 0.3, 1, 3, 6, or 10 mg/kg). Serum concentrations of golimumab were determined using a validated enzyme-linked immunosorbent assay method. In addition to the noncompartmental analysis and compartmental modeling, a population pharmacokinetics analysis using NONMEM was also conducted. Both the maximum serum concentration and the area under the serum concentrationtime curve appeared to increase in a dose-proportional manner. The median half-life ranged from 7 to 20 days. A 2-compartment population pharmacokinetic model adequately described the pharmacokinetics of golimumab. The following pharmacokinetic parameters (typical value [% coefficient of variation]) were estimated from the population pharmacokinetic model: clearance (CL: 0.40 [10.1%] L/d), volume of distribution in the central compartment (V(c): 3.07 [6.4%] L), intercompartmental clearance (Q: 0.42 [15.5%] L/d), and volume of distribution in the peripheral compartment (V(p): 3.68 [11.8%] L). Interindividual variability of the pharmacokinetic parameters was quantified for CL (44.3%), V(c) (25.5%), Q (44.6%), and V(p) (44.6%). Residual variability was estimated to be 15.0%. Body weight was found to be an important covariate on V(c). Golimumab was generally well tolerated. The pharmacokinetics of golimumab appeared to be linear over the dose range evaluated in this study.
authors.affiliation: Clinical Pharmacology & Experimental Medicine, Centocor Research & Development, 200 Great Valley Parkway, Malvern, PA 19355, USA. hzhou2@cntus.jnj.com
authors.forename: Honghui
authors.initials: H
authors.lastname: Zhou
authors.forename: Haishan
authors.initials: H
authors.lastname: Jang
authors.forename: Roy M
authors.initials: RM
authors.lastname: Fleischmann
authors.forename: Esther
authors.initials: E
authors.lastname: Bouman-Thio
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Xu
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Marini
authors.forename: Charles
authors.initials: C
authors.lastname: Pendley
authors.forename: Qun
authors.initials: Q
authors.lastname: Jiao
authors.forename: Gopi
authors.initials: G
authors.lastname: Shankar
authors.forename: Stanley J
authors.initials: SJ
authors.lastname: Marciniak
authors.forename: Stanley B
authors.initials: SB
authors.lastname: Cohen
authors.forename: Mahboob U
authors.initials: MU
authors.lastname: Rahman
authors.forename: Daniel
authors.initials: D
authors.lastname: Baker
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Mascelli
authors.forename: Hugh M
authors.initials: HM
authors.lastname: Davis
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Everitt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004797:Enzyme-Linked Immunosorbent Assay; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha